Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/43244
Title: Participant acceptability of exercise in kidney disease (PACE-KD): a feasibility study protocol in renal transplant recipients.
Authors: Bishop, NC
Billany, R
Smith, AC
First Published: 24-Sep-2017
Publisher: BMJ Publishing Group
Citation: BMJ Open, 2017, 7 (9), pp. e017494-?
Abstract: INTRODUCTION: Cardiovascular disease (CVD) is a major cause of mortality in renal transplant recipients (RTRs). General population risk scores for CVD underestimate the risk in patients with chronic kidney disease (CKD) suggesting additional non-traditional factors. Renal transplant recipients also exhibit elevated inflammation and impaired immune function. Exercise has a positive impact on these factors in patients with CKD but there is a lack of rigorous research in RTRs, particularly surrounding the feasibility and acceptability of high-intensity interval training (HIIT) versus moderate-intensity continuous training (MICT) in this population. This study aims to explore the feasibility of three different supervised aerobic exercise programmes in RTRs to guide the design of future large-scale efficacy studies. METHODS AND ANALYSIS: Renal transplant recipients will be randomised to HIIT A (16 min interval training with 4, 2 and 1 min intervals at 80%-90% of peak oxygen uptake (VO2 peak)), HIIT B (4×4 min interval training at 80%-90% VO2peak) or MICT (~40 min cycling at 50%-60% VO2peak) where they will undertake 24 supervised sessions (approximately thrice weekly over 8 weeks). Assessment visits will be at baseline, midtraining, immediate post-training and 3 months post-training. The study will evaluate the feasibility of recruitment, randomisation, retention, assessment procedures and the implementation of the interventions. A further qualitative sub-study QPACE-KD (Qualitative Participant Acceptability of Exercise in Kidney Disease) will explore patient experiences and perspectives through semistructured interviews and focus groups. ETHICS AND DISSEMINATION: All required ethical and regulatory approvals have been obtained. Findings will be disseminated through conference presentations, public platforms and academic publications. TRIAL REGISTRATION NUMBER: Prospectively registered; ISRCTN17122775.
DOI Link: 10.1136/bmjopen-2017-017494
eISSN: 2044-6055
Links: https://bmjopen.bmj.com/content/7/9/e017494
http://hdl.handle.net/2381/43244
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © the authors, 2017. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation



Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.